Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein
Diabetes/Metabolism Research and Reviews2010Vol. 26(4), pp. 287–296
Citations Over TimeTop 10% of 2010 papers
Wolfgang Glaesner, Andrew Vick, Rohn Millican, Bernice Ellis, Sheng‐Hung Tschang, Yu Tian, Krister Bokvist, Martin Brenner, Anja Köester, Niels Pörksen, Garret J. Etgen, Tom Bumol
Abstract
LY2189265 retains the effects of GLP-1 with increased half-life and efficacy, supporting further evaluation as a once-weekly treatment of type 2 diabetes.
Related Papers
- → Molecular characterization of dipeptidyl peptidase activity in serum(2000)271 cited
- → Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries(2011)72 cited
- → Obese patients have higher circulating protein levels of dipeptidyl peptidase IV(2014)58 cited
- → Human serum dipeptidyl peptidase IV (DPPIV) and its unique properties(1996)5 cited
- → CD26/dipeptidyl peptidase IV (DPPIV, DAPIV) is a useful molecular marker for thyroid carcinomas(2013)